As part of our commitment to security, this website may experience intermittent downtime between 8 am and 10 am ET to apply updates through the end of September.



Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Read More